These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24078983)

  • 1. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
    Deepak P; Stobaugh DJ
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS; Richardson P; Castillo D; Kane SV
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
    Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.
    Parakkal D; Sifuentes H; Semer R; Ehrenpreis ED
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1150-6. PubMed ID: 21941193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
    Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
    Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
    Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
    Ward MG; Irving PM; Sparrow MP
    World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious and malignant complications of TNF inhibitor therapy in IBD.
    Targownik LE; Bernstein CN
    Am J Gastroenterol; 2013 Dec; 108(12):1835-42, quiz 1843. PubMed ID: 24042192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Shukla T; Singh S; Tandon P; McCurdy JD
    J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Campos S; Portela F; Sousa P; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.